Chamorro, Diego F.
Cardona, Andrés F.
Rodríguez, July
Ruiz-Patiño, Alejandro
Arrieta, Oscar
Moreno-Pérez, Darwin A.
Rojas, Leonardo
Zatarain-Barrón, Zyanya Lucia
Ardila, Dora V.
Viola, Lucia
Recondo, Gonzalo
Blaquier, Juan B.
Martín, Claudio
Raez, Luis
Samtani, Suraj
Ordóñez-Reyes, Camila
Garcia-Robledo, Juan Esteban
Corrales, Luis
Sotelo, Carolina
Ricaurte, Luisa
Cuello, Mauricio
Mejía, Sergio
Jaller, Elvira
Vargas, Carlos
Carranza, Hernán
Otero, Jorge
Archila, Pilar
Bermudez, Maritza
Gamez, Tatiana
Russo, Alessandro
Malapelle, Umberto
de Miguel Perez, Diego
de Lima, Vladmir C. Cordeiro
Freitas, Helano
Saldahna, Erick
Rolfo, Christian
Rosell, Rafael
,
Funding for this research was provided by:
Universidad El Bosque
Article History
Accepted: 19 February 2023
First Online: 5 April 2023
Declarations
:
: This study was sponsored by the stipend PCI-2018-10171 of Universidad El Bosque (Bogotá, Colombia) and approved by the Institutional Ethics Committee (reference No. 019-2021). The CLICaP and the Foundation for Clinical and Applied Cancer Research—FICMAC (Bogotá, Colombia) supported some lab experiments through research grant 023-2019.
: Andrés F. Cardona discloses financial research support from Merck Sharp & Dohme, Boehringer Ingelheim, Roche, Bristol-Myers Squibb, and the Foundation for Clinical and Applied Cancer Research—FICMAC. Additionally, he was linked to and received honoraria as an advisor to, participated in speakers' bureau for, and gave expert testimony to Merck Sharp & Dohme, Boehringer Ingelheim, Roche, Bristol-Myers Squibb, Pfizer, Novartis, Celldex Therapeutics, Foundation Medicine, Eli Lilly, and the Foundation for Clinical and Applied Cancer Research—FICMAC. Oscar Arrieta reports personal fees from Pfizer, grants and individual fees from Astra Zeneca, grants and individual fees from Boehringer-Ingelheim, personal fees from Lilly, individual fees from Merck, personal fees from Bristol Myers Squibb, and grants and personal fees from Roche, outside the submitted work. Gonzalo Recondo reports personal fees from Pfizer, Roche, Amgen, Bayer, Takeda, MSD, and Merck Serono, and research grants from Amgen and Janssen, outside of the submitted work. Juan Blaquier has nothing to disclose.
: All included patients provided signed informed consent. In addition, an Institutional Review Board and Privacy Board waiver was obtained to facilitate retrospective clinical-pathological and molecular data (Lung Cancer-FICMAC/CLICaP Platform—Registration No. 2012/014, Kayre, Bogotá, Colombia, and Research Ethics Committee of Universidad El Bosque—Registration No. PCI-2018-10171).
: See the ethics approval statement.
: Not applicable.
: Not applicable.